• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.

作者信息

Faucette Stephanie, Wagh Santosh, Trivedi Ashit, Venkatakrishnan Karthik, Gupta Neeraj

机构信息

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.

Clinical Pharmacology, Amgen Inc., Thousand Oaks, California, USA.

出版信息

Clin Transl Sci. 2018 Mar;11(2):123-146. doi: 10.1111/cts.12527. Epub 2017 Dec 19.

DOI:10.1111/cts.12527
PMID:29266809
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5867000/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6684/5867000/d6e2577f00d7/CTS-11-123-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6684/5867000/9607ebcb26a8/CTS-11-123-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6684/5867000/0a43b486e101/CTS-11-123-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6684/5867000/d6e2577f00d7/CTS-11-123-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6684/5867000/9607ebcb26a8/CTS-11-123-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6684/5867000/0a43b486e101/CTS-11-123-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6684/5867000/d6e2577f00d7/CTS-11-123-g003.jpg

相似文献

1
Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.美国食品药品监督管理局对2011 - 2017年批准的肿瘤学新分子实体的反向翻译：抗癌药物开发的经验教训
Clin Transl Sci. 2018 Mar;11(2):123-146. doi: 10.1111/cts.12527. Epub 2017 Dec 19.
2
Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology.肿瘤学中伴随诊断开发的临床和监管方面。
Clin Pharmacol Ther. 2018 Jun;103(6):999-1008. doi: 10.1002/cpt.955. Epub 2017 Dec 20.
3
FDA regulatory considerations for oncology drug development.美国食品药品监督管理局对肿瘤药物研发的监管考量
Pharmacol Res Perspect. 2024 Aug;12(4):e1254. doi: 10.1002/prp2.1254.
4
Cancer drugs remain FDA approved despite lack of benefit, study finds.研究发现，尽管抗癌药物并无益处，但仍获美国食品药品监督管理局批准。
BMJ. 2016 Dec 6;355:i6568. doi: 10.1136/bmj.i6568.
5
Premarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication Approvals.实时肿瘤学审查适应症批准的上市前证据和上市后要求。
JAMA Netw Open. 2024 May 1;7(5):e249233. doi: 10.1001/jamanetworkopen.2024.9233.
6
Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in Oncology.口服药物的食物影响研究设计：肿瘤学中最近批准药物的经验教训。
J Clin Pharmacol. 2019 Apr;59(4):463-471. doi: 10.1002/jcph.1351. Epub 2018 Dec 10.
7
Pediatric Development of Molecularly Targeted Oncology Drugs.儿科分子靶向肿瘤药物的发展。
Clin Pharmacol Ther. 2018 Aug;104(2):384-389. doi: 10.1002/cpt.942. Epub 2017 Dec 11.
8
Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?监管观察：肿瘤药物为何未能获得美国监管批准？
Nat Rev Drug Discov. 2015 Jul;14(7):450-1. doi: 10.1038/nrd4651. Epub 2015 May 22.
9
Factors That Influence FDA Decisions for Postmarketing Requirements and Commitments During Review of Oncology Products.影响 FDA 在审查肿瘤产品时做出上市后要求和承诺决策的因素。
J Oncol Pract. 2018 Jan;14(1):e34-e41. doi: 10.1200/JOP.2017.023234. Epub 2017 Nov 14.
10
Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities.儿童适用癌症药物的获批情况：立法举措的影响和未来机遇。
Pediatr Blood Cancer. 2019 Aug;66(8):e27809. doi: 10.1002/pbc.27809. Epub 2019 May 30.

引用本文的文献

1
Optimizing Brentuximab Vedotin Dosing in Pediatric Patients with Advanced Hodgkin Lymphoma: A Population Pharmacokinetic and Exposure-Response Analysis.优化晚期霍奇金淋巴瘤儿科患者的维布妥昔单抗给药剂量：一项群体药代动力学和暴露-反应分析
Clin Pharmacol Ther. 2025 Jun;117(6):1803-1810. doi: 10.1002/cpt.3629. Epub 2025 Mar 17.
2
Assessment of Food Effect and pH-Dependent Drug-Drug Interactions of Fruquintinib in Healthy Subjects.呋喹替尼在健康受试者中的食物效应及pH依赖性药物相互作用评估。
Clin Transl Sci. 2025 Mar;18(3):e70168. doi: 10.1111/cts.70168.
3
Playing Hide-and-Seek with Tyrosine Kinase Inhibitors: Can We Overcome Administration Challenges?

本文引用的文献

1
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.在先前接受过≥2种HER2靶向治疗方案的晚期乳腺癌患者中，曲妥珠单抗恩美曲妥珠单抗的群体药代动力学和暴露-反应关系。
Br J Clin Pharmacol. 2017 Dec;83(12):2767-2777. doi: 10.1111/bcp.13381. Epub 2017 Sep 3.
2
Recent developments in the science of proarrhythmic cardiac safety of new drugs.新药致心律失常心脏安全性科学的最新进展。
Eur Heart J Cardiovasc Pharmacother. 2017 Apr 1;3(2):118-124. doi: 10.1093/ehjcvp/pvw045.
3
Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis.
与酪氨酸激酶抑制剂玩捉迷藏：我们能否克服给药挑战？
AAPS J. 2024 Jun 11;26(4):66. doi: 10.1208/s12248-024-00939-1.
4
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach.采用基于生理的药代动力学建模方法评估布加替尼的药物相互作用潜力。
CPT Pharmacometrics Syst Pharmacol. 2024 Apr;13(4):624-637. doi: 10.1002/psp4.13106. Epub 2024 Jan 30.
5
Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor.布加替尼的临床药理学：下一代间变性淋巴瘤激酶抑制剂。
Clin Pharmacokinet. 2023 Aug;62(8):1063-1079. doi: 10.1007/s40262-023-01284-w. Epub 2023 Jul 26.
6
Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis.参与结直肠癌肝转移发生和发展的受体酪氨酸激酶的蛋白质组定量分析。
Front Oncol. 2023 Feb 20;13:1010563. doi: 10.3389/fonc.2023.1010563. eCollection 2023.
7
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development.肿瘤临床药物开发中建模和模拟实践的全面监管和行业审查。
J Pharmacokinet Pharmacodyn. 2023 Jun;50(3):147-172. doi: 10.1007/s10928-023-09850-2. Epub 2023 Mar 4.
8
Clinical pharmacology information in regulatory submissions and labeling: A comparative analysis of orphan and non-orphan drugs approved by the FDA.监管提交和标签中的临床药理学信息：FDA 批准的孤儿药和非孤儿药的比较分析。
Clin Transl Sci. 2022 Nov;15(11):2583-2596. doi: 10.1111/cts.13362. Epub 2022 Sep 27.
9
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.评价利福平对晚期实体瘤患者中 NEDD8 激活酶抑制剂培维替尼药代动力学影响的 1 期研究。
Invest New Drugs. 2022 Oct;40(5):1042-1050. doi: 10.1007/s10637-022-01286-8. Epub 2022 Aug 6.
10
Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.MET 抑制剂 tepotinib 的暴露-反应分析，包括关键性 VISION 试验中的患者：支持剂量建议。
Cancer Chemother Pharmacol. 2022 Jul;90(1):53-69. doi: 10.1007/s00280-022-04441-3. Epub 2022 Jun 30.
纳武利尤单抗的时变清除率与疾病动态的关联及其对暴露-反应分析的影响
Clin Pharmacol Ther. 2017 May;101(5):657-666. doi: 10.1002/cpt.656. Epub 2017 Mar 22.
4
Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels: Frequent utilization in the field of oncology.基于生理的药代动力学模型对监管审评和产品标签的影响：在肿瘤学领域的频繁应用。
Clin Pharmacol Ther. 2017 May;101(5):597-602. doi: 10.1002/cpt.622. Epub 2017 Mar 15.
5
Food Effect Studies for Oncology Drug Products.肿瘤药物产品的食物效应研究。
Clin Pharmacol Ther. 2017 May;101(5):606-612. doi: 10.1002/cpt.610. Epub 2017 Mar 20.
6
PBPK modeling and simulation in drug research and development.药物研发中的生理药代动力学（PBPK）建模与模拟
Acta Pharm Sin B. 2016 Sep;6(5):430-440. doi: 10.1016/j.apsb.2016.04.004. Epub 2016 Jun 23.
7
Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.提高临床药效学在肿瘤药物研发中的价值：定量药理学与转化科学的联盟
Clin Pharmacol Ther. 2017 Jan;101(1):99-113. doi: 10.1002/cpt.544. Epub 2016 Nov 25.
8
Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs.新药致心律失常风险评估的不断演变的监管范式
J Electrocardiol. 2016 Nov-Dec;49(6):837-842. doi: 10.1016/j.jelectrocard.2016.07.017. Epub 2016 Jul 28.
9
Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.基于 CYP3A4 代谢酶诱导剂相互作用潜力的伊布替尼给药策略：应用生理药代动力学模型。
Clin Pharmacol Ther. 2016 Nov;100(5):548-557. doi: 10.1002/cpt.419. Epub 2016 Aug 27.
10
Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of Lemborexant.作为评估QT风险的替代临床和监管方法的早期临床研究心电图数据浓度-反应建模——来自lemborexant研发项目的经验
J Clin Pharmacol. 2017 Jan;57(1):96-104. doi: 10.1002/jcph.785. Epub 2016 Aug 4.